Lymphoma

Two-year survivors with relapsed Hodgkin lymphoma or diffuse large B-cell lymphoma after transplant had an excess late mortality risk vs the general population.

Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.

The FDA has granted accelerated approval to acalabrutinib (Calquence) for the treatment of mantle cell lymphoma in adult patients who have received at least one previous therapy.

The number of extranodal sites of disease did not influence outcomes among young patients with high-risk DLBCL treated with rituximab-dose-dense chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation.

Elderly patients, including those treated with an R-CHOP regimen, tend to have poor outcomes regardless of salvage therapy.

The pharmaceutical company AstraZeneca retracted a paper and acknowledged that some preclinical data were falsified regarding its developmental agent acalabrutinib, which is under investigation for use in a number of malignancies.

The FDA has approved the CAR T-cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B-cell lymphomas in adults who have failed or relapsed after two or more prior treatments.

A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.

In this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.

There is a high economic burden associated with the treatment of relapsed or refractory Hodgkin lymphoma. A recent study found that patients undergoing treatment for the disease incurred a median total all-cause cost of about $300,000.

Treatment with obinutuzumab along with chemotherapy resulted in longer progression-free survival than rituximab and chemotherapy in patients with previously untreated advanced-stage follicular lymphoma, according to a large randomized trial.

Maintenance therapy with rituximab following autologous stem cell transplantation prolonged progression-free, event-free, and overall survival compared with observation in patients with mantle cell lymphoma, according to a new study.

A new study identified simple risk factors that could help identify patients with extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) at high risk for poor outcomes.

The FDA has approved the novel PI3K inhibitor copanlisib (Aliqopa) for the treatment of relapsed follicular lymphoma in adult patients who have received at least two prior systemic therapies.

The US Food and Drug Administration has granted Priority Review to obinutuzumab in combination with chemotherapy and followed by obinutuzumab alone for treatment-naïve follicular lymphoma.

Adding obinutuzumab to cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) failed to improve progression-free survival compared with rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma.

In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.

Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States.

Arsenic trioxide consolidation was well tolerated in pediatric patients with acute promyelocytic leukemia and allowed for significant reductions in cumulative anthracycline doses.

Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study.

The FDA has approved a fixed combination of daunorubicin and cytarabine (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes.

Patients with primary immunodeficiency diseases are at increased risk of certain cancers, according to a new study. The strongest association was with lymphoma.

The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.

Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study.

A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.

Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study.

The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.

Treatment of adult relapsed or refractory acute lymphoblastic leukemia with inotuzumab ozogamicin was associated with increased hepatotoxicity, especially after follow-up hematopoietic stem cell transplantation.